Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailor-made ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals.
Syngene’s unique business model allows us to offer R&D services that are flexible and are designed to suit our client’s needs. Starting with a single service (component play), our client engagement gradually leads to an expanded scope of services (cluster play) and eventually into an integrated play, where we engage across multiple platforms, including setting up Dedicated Centers.
The Dedicated Centers involve long-term strategic collaborations, usually for five year periods or longer. As part of these long- term collaborations, Syngene sets up a dedicated, customised and ring-fenced infrastructure, in line with our client’s requirements. These Dedicated Centers are generally multi-disciplinary, full time equivalent (FTE)based engagements that support a wide array of integrated R&D requirements of our clients.
Most Dedicated Centers have client staff co-located in the Dedicated Center premises, thereby creating an ideal collaborative environment with real-time and continuous exchange of ideas that fosters creativity and learning for all stakeholders
Biocon Bristol Myers Squibb research and development center (BBRC)
Syngene has been closely associated with Bristol Myers Squibb (BMS) since 1998. In 2007, Syngene set up BBRC, a dedicated research facility for BMS to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development.
Since its inception, BBRC has produced 10 drug candidates for further studies, and has also helped BMS reduce the time and costs associated with advancing new compounds to first-in-human studies. One drug candidate currently in clinical trials, was discovered at BBRC, and early nonclinical development work done at BBRC has enabled most of BMS’s small molecule assets to advance to later stages of development over the last five years.
This facility is the largest research and development center for BMS outside the United States and Europe. It houses ~600 scientists and is spread across more than ~200,000 sq ft of dedicated laboratory and office space in Syngene’s Bengaluru campus
Baxter global research center (BGRC)
Syngene and Baxter International Inc., a leading global pharmaceutical company, have collaborated to establish the Baxter global research center (BGRC) at Syngene’s Bangalore premises. This Dedicated Center, supports Baxter in the research and development of medical products and devices to serve patients around the world.
A team of over 200 multidisciplinary Syngene scientists work closely with Baxter scientists on a wide array of R&D activities, centred on product and analytical development and pre-clinical evaluation in parenteral nutrition and renal therapy. The scale and scope of activities signal the strategic nature of the collaboration, and reflect Syngene’s capabilities to offer broad-based, complementary and integrated development services.
Syngene Amgen research and development center (SARC)
Syngene Amgen research and development center (SARC) is a dedicated multi-disciplinary drug discovery and development center set up for Amgen Inc. in Bengaluru. SARC has been customized to Amgen’s requirements and complies with the highest regulatory standards. It is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and “green” chemistry.
Initially setup with a lab space of 25,000 sq. ft and a team of around 100 scientists, it was subsequently expanded to more than 60,000 sq. ft. of dedicated lab space with a team of more than 170 scientists. This scientific team works closely with Amgen’s global R&D team on various projects spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development.
Read full press release
Read full press release